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Abstract
Community Acquired Methicillin Resistant Staphylococcus aureus (CA-MRSA) causes severe necrotizing infections of the skin,
soft tissues, and lungs. Staphylococcal a-hemolysin is an essential virulence factor in mouse models of CA-MRSA necrotizing
pneumonia. S. aureus a-hemolysin has long been known to induce inflammatory signaling and cell death in host organisms,
however the mechanism underlying these signaling events were not well understood. Using highly purified recombinant a-
hemolysin, we now demonstrate that a-hemolysin activates the Nucleotide-binding domain and leucine-rich repeat
containing gene family, pyrin domain containing 3 protein (NLRP3)-inflammasome, a host inflammatory signaling complex
involved in responses to pathogens and endogenous danger signals. Non-cytolytic mutant a-hemolysin molecules fail to
elicit NLRP3-inflammasome signaling, demonstrating that the responses are not due to non-specific activation of this innate
immune signaling system by bacterially derived proteins. In monocyte-derived cells from humans and mice, inflammasome
assembly in response to a-hemolysin results in activation of the cysteine proteinase, caspase-1. We also show that
inflammasome activation by a-hemolysin works in conjunction with signaling by other CA-MRSA-derived Pathogen
Associated Molecular Patterns (PAMPs) to induce secretion of pro-inflammatory cytokines IL-1b and IL-18. Additionally, a-
hemolysin induces cell death in these cells through an NLRP3-dependent program of cellular necrosis, resulting in the
release of endogenous pro-inflammatory molecules, like the chromatin-associated protein, High-mobility group box 1
(HMGB1). These studies link the activity of a major S. aureus virulence factor to a specific host signaling pathway. The cellular
events linked to inflammasome activity have clear relevance to the disease processes associated with CA-MRSA including
tissue necrosis and inflammation.
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Introduction
CA-MRSA is the most commonly identified cause of skin
infections seen in emergency rooms in the United States [1]. CA-
MRSA can also cause severe, life threatening infections including
necrotizing pneumonias and fasciitis, which are associated with
very high mortality rates even in previously healthy patients [2,3].
These necrotizing infections are characterized by localized
necrosis and severe inflammation. People colonized with CA-
MRSA suffer from some form of S. aureus infection at rates about
seven times higher than people colonized with other S. aureus
strains [4]. In addition to resistance to our most commonly used
anti-staphylococcal antibiotics, CA-MRSA has increased virulence
that is associated with the production of specific factors that assist
this pathogen in causing disease [5].
All S. aureus produce secreted exotoxin virulence factors
including several cytolytic, pore-forming toxins [6]. Both a-
hemolysin (Hla) and Panton Valentine leukocidin (PVL) have been
implicated in the pathogenesis of S. aureus necrotizing pneumonia
[7,8]. Pulmonary delivery of purified a-hemolysin has been shown
to induce pulmonary hypertension and inflammation in rat and
rabbit [9,10]. Similar studies in mice with PVL have show that
PVL can induce pulmonary inflammation and pneumonitis in
mice, in the absence of the bacteria that produce it [8]. More
recently, a-hemolysin has been shown to be required for S. aureus
strains, including CA-MRSA, to promote pneumonia in a mouse
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hemolysin protects mice from S. aureus pneumonia and prevents
production of IL-1b and other cytokines associated with
pulmonary exposure to S. aureus [12]. Most recently, passive
immunization with a-hemolysin-neutralizing antibodies has been
shown to protect mice from fatal S. aureus pneumonia [12,13].
In addition to inducing pulmonary inflammation, S. aureus a-
hemolysin has been shown to induce inflammatory reactions in the
eye, skin, and abdomen when injected into rodents [14,15,16].
The mechanisms by which a-hemolysin induces inflammation in
these intact animals have not been fully evaluated. In endothelial
cells, a-hemolysin induces platelet activating factor production
[17,18,19]. In pulmonary epithelial derived cell lines, exposure to
a-hemolysin causes release of nitric oxide and other inflammatory
mediators [20]. a-hemolysin has also been shown to act
synergistically with S. aureus particles to induce some cytokine
secretion, including IL-6 and IL-1a in mouse peritoneal
macrophages [21]. Finally, a-hemolysin has been shown to induce
cell death and IL-1b secretion from human monocytes [22]. The
intracellular signaling mechanisms that link a-hemolysin to
secretion of cytokines and other inflammatory mediators are
unknown.
Physiologic inflammatory signaling can be triggered by
pathogen and host derived molecules. The family of nucleotide
binding domain and leucine rich repeat containing proteins known
as NLR (formerly NALP, NOD, PYPAF, and CATERPILLER)
have recently been implicated in several different inflammatory
signaling pathways [23,24]. Mutations in the gene encoding the
NLR family member, NLRP3, are associated with hyperactive
inflammatory signaling characterized by excessive IL-1b
[25,26,27]. Many NLR proteins, including NLRP3, have been
found to oligomerize into a macromolecular complex known as
the inflammasome [28,29]. The NLRP3-inflammasome is a
signaling complex that activates procaspase-1 and induces
processing of caspase-1 dependent inflammatory cytokines (par-
ticularly IL-1b and IL-18). The NLRP3-inflammasome is
activated in response to a multitude of pro-inflammatory stimuli,
including many pathogen-derived molecules, endogenous inducers
of sterile inflammation, and non-pathogen microbial pore-forming
toxins, including nigericin and maitotoxin [30,31,32,33,34,35].
Recently, activation of NLRP3 has been found to initiate both
caspase-1 dependent cytokine production and a caspase-indepen-
dent pro-inflammatory program of necrotic cell death [36,37].
Living S. aureus activates NLRP3-mediated signaling in cell
culture, but the S. aureus-derived factors involved in initiating this
signaling remained to be identified [32]. We now show that S.
aureus a-hemolysin induces NLRP3-mediated signaling triggering
caspase-1 activation and programmed necrosis.
Results
Prior studies have demonstrated that S. aureus a-hemolysin could
induce IL-1b secretion in human monocytes [22]. We sought to
determine whether we could see similar induction of IL-1b
secretion by a-hemolysin in THP-1 cells, a human monocyte-
derived cell line. Commercial preparations of a-hemolysin are
relatively crude, with manufacturers reporting ,50% of prepara-
tions being protein and the homogeneity of the protein present not
reported. In order to study a-hemolysin-induced inflammatory
signaling we sought to prepare highly purified S. aureus a-
hemolysin. Recombinant a-hemolysin bearing a hexa-histidine-
tag was prepared after expression in Escherichia coli. The
recombinant a-hemolysin was isolated from crude E. coli
homogenates using immobilized metal affinity chromatography.
In order to eliminate the possibility of E. coli LPS contamination of
our preparation, the protein was washed extensively in pyrogen
free buffers. After elution, the recombinant protein was exchanged
into pyrogen free phosphate buffed saline using size exclusion
chromatography. The resulting recombinant a-hemolysin runs as
a single homogenous protein band on Coomasie Blue stained SDS
PAGE (Fig. 1A). This protein is immunoreactive with multiple
anti-a- hemolysin antibodies (Fig. 1B & Fig. 2C). This preparation
of a-hemolysin induced IL-1b secretion from THP-1 cells (Fig. 1C).
In order to confirm that the ability to activate IL-1b secretion
depended on functional a-hemolysin, and not a contaminating
substance in the preparation, we prepared an inactive mutant of a-
hemolysin (H35L) that lacks hemolytic activity [12]. The mutant
a-hemolysin was highly purified, just as the wild-type preparation,
yet failed to elicit IL-1b secretion (Fig. 1A, B, & C). A monoclonal
antibody that neutralizes a-hemolysin activity and has been shown
to protect mice from S. aureus pneumonia also reduced IL-1b
secretion induced by a-hemolysin when preincubated with the
toxin prior to treatment of the cells (Fig. 1D) [13]. In order to
demonstrate that a-hemolysin was inducing IL-1b secretion
through activation of caspase-1, caspase-1 activation was assessed
by immunoblot analysis for the p10 subunit of active caspase-1
after THP-1 cells were treated with wild type or H35L mutant a-
hemolysin. Caspase-1 p10 was observed only in cells treated with
active a-hemolysin (Fig. 1E). These data all support the hypothesis
that a-hemolysin activates IL-1b processing and secretion in a
manner similar to other non-pathogen derived pore forming
toxins, nigericin and maitotoxin [32].
Unlike preparations of highly purified a-hemolysin, treatment of
resting THP-1 cells with commercial preparations of a-hemolysin
did not induce detectable levels of IL-1b secretion (Fig. 2A). We
sought to further characterize these commercial preparations of a-
hemolysin. Using SDS-PAGE and Coomassie Blue protein
staining, we found that these preparations contained at least 3
predominant protein bands (Fig. 2B). Immunoblot analysis of these
proteins using antibodies directed to a-hemolysin revealed only a
single band of immunoreactivity, suggesting the additional
proteins within the preparation were derived from other S. aureus
proteins rather than proteolysis of a-hemolysin (Fig. 2C). These
data indicate that significantly less a-hemolysin was added the
cells, when compared to highly purified recombinant a-hemolysin.
Production of mature IL-1b is frequently studied in cells
pretreated with lipopolysaccharide (LPS) or other Toll-like
receptor (TLR) agonists, which are thought to induce expression
of pro-IL-1b. Indeed studies demonstrating that secretion of IL-1b
could be induced by a-hemolysin were carried out in LPS-treated
monocytes [22]. Because S. aureus does not produce LPS, we
sought to determine whether priming of THP-1 cells with heat
killed S. aureus (HKSA) could support IL-1b secretion in a manner
analogous to LPS treatment. Treatment of THP-1 cells with heat
killed S. aureus also resulted in minimal IL-1b secretion (Fig. 2A).
However, exposure of HKSA-primed THP-1 cells to either
commercial or recombinant a-hemolysin induced more robust
IL-1b secretion (Fig. 2A). Consistent with its lower a-hemolysin
content, the commercial a-hemolysin preparation induced less IL-
1b secretion than an equivalent dose of recombinant a-hemolysin.
Two S. aureus derived TLR ligands [38,39,40], peptidoglycan,
PGN, (TLR2) and lipotechoic acid, LTA, (TLR4) also caused a
synergistic induction of IL-1b secretion in conjunction with a-
hemolysin treatment, while causing little or no IL-1b secretion by
themselves (Fig. 2D). Immunoblot analysis of cell lysates treated
with HKSA, a-hemolysin, or both demonstrated that HKSA did
indeed induce production of pro-IL-1b while a hemolysin alone
did not (Fig. 2E). Processing of IL-1b, reflected by reduced pro-IL-
a-Hemolysin Activates NLRP3
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detected by immunoblot in the HKSA-primed, a-hemolysin-
treated cells (Fig. 2E). These data suggest that a-hemolysin acts
downstream of pro-IL-1b synthesis, at the level of processing or
secretion, in order to induce IL-1b secretion. Overall, these data
demonstrate that multiple S. aureus-derived TLR ligands enchance
a-hemolysin-induced IL-1b secretion, though they are not
required for caspase-1 activation.
The NLRP3 inflammasome has been identified as a critical
signaling complex involved in activation of caspase-1 and
subsequent IL-1b secretion in response to many inflammatory
stimuli, including nigericin and maitotoxin [32,41]. We sought
evidence that the NLRP3 inflammasome was required for a-
hemolysin mediated IL-1b secretion. For these studies, we utilized
THP-1 derived cell lines that have been transduced with
recombinant retrovirus expressing shRNA that ‘‘knock down’’
expression of the inflammasome components, ASC or NLRP3
[36,42]. When compared to control cell lines expressing no
shRNA or a scrambled shRNA, cells lacking expression of either
NLRP3 or ASC failed to mount robust IL-1b secretion responses
to a-hemolysin treatment (Fig. 3A). To confirm these findings, we
carried out a similar set of experiments in peritoneal macrophages
from C57Bl/6 mice with genetic knock out of several inflamma-
some components: Nlrp3
2/2, Asc
2/2, and Casp1
2/2. IL-1b
secretion was reduced in HKSA-primed, a-hemolysin-treated
peritoneal macrophages derived from Nlrp3
2/2, Asc
2/2, and
Casp1
2/2 mice when compared to wild-type controls (Fig. 3B). We
also sought further evidence that a-hemolysin was inducing IL-1b
secretion through NLRP3-inflammasome dependent activation of
caspase-1. We tested whether a-hemolysin treatment also led to
the secretion of IL-18, another caspase-1 processed cytokine. As
expected, control THP-1 cells secreted IL-18 in response to a-
hemolysin. Like IL-1b secretion, IL-18 secretion was also
enhanced by pretreatment with HKSA. THP-1 cells lacking
Figure 1. S. aureus a-hemolysin induces IL-1b secretion and caspase-1 activation in THP-1 cells. (A) recombinant hexahistidine-tagged a-
hemolysin preparations were analyzed by SDS-PAGE and Coomassie Blue staining. Both Wild Type (W.T.) and inactive mutant (H35L) Hla were
prepared as described in the materials and methods. (B) The Hla preparations described in (A) were analyzed by immunoblot analysis using
polyclonal antisera directed against S. aureus a-hemolysin, Abcam product # ab15948. (C) THP-1 cells were untreated (N.T.) or treated with each of
the a-hemolysin preparations described in (A) for 1 hour. The cell culture supernatants were analyzed for secreted IL-1b using ELISA. Asterisk (*)
denotes cytokine levels below detectable limits (4 pg/ml). (D) Wild type a-hemolysin was prepared with the addition of saline (Hla), control IgG (Hla +
IgG), or anti-a-hemolysin IgG (Hla + anti-Hla). THP-1 cells were untreated (N.T.) or treated with the aforementioned a-hemolysin preparations for
1 hour. The cell culture supernatants were analyzed for secreted IL-1b using ELISA. (E) THP-1 cells were either untreated (N.T.) or treated with highly
purified recombinant a-hemolysin (W.T. or H35L) for 1 hour, cell lysates were prepared and analyzed by immunoprecipitation and immunoblot
analysis for the p10 subunit of activated caspase-1 and actin (loading control) as described in the materials and methods. The double arrow («)
indicates the position of protein G used in immunoprecipitation, which binds immunoblot antibodies nonspecifically. Representative data from at
least 3 independent experiments are shown.
doi:10.1371/journal.pone.0007446.g001
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without Heat Killed S. aureus (HKSA, 10
6 particle/ml) for 3 hours then subsequently treated with 1.0 mg/ml a-hemolysin preparations, commercial
(Com.) or recombinant a-hemolysin (rHla) described in Fig. 1, for 1 hour. The cell culture supernatants were subsequently analyzed for secreted IL-1b
using ELISA. (B) Commercial (Com.) a-hemolysin from Sigma Aldrich and recombinant (Rec.), hexahistidine-tagged a-hemolysin preparations were
analyzed by SDS-PAGE and Coomassie Blue staining. Both Wild Type (W.T.) and inactive mutant (H35L) Hla were prepared as described in the
materials and methods. (C) The Hla preparations described in (B) were analyzed by immunoblot analysis using polyclonal antibodies directed against
S. aureus a-hemolysin (Toxin Technologies product # SLHI101). (D) THP-1 cells were untreated (N.T.) or treated with Heat Killed S. aureus (HKSA, 10
6
particle/ml), S. aureus lipotechoic acid (LTA, 100 ng/ml), or S. aureus peptidoglycan (PGN, 100 ng/ml) for 3 hours. The cells were subsequently treated
either with or without S. aureus hemolysin (Hla, 1.0 mg/ml, Sigma Aldrich) for an additional 1 hour. IL-1b secretion into the culture media was
measured using ELISA. Asterisk (*) denotes cytokine levels below detectable limits (4 pg/ml). Representative data from at least 3 independent
experiments are shown. (E) THP-1 cells were treated as described in (A) with Heat Killed S. aureus (HKSA) followed by commercial (Hla) or recombinant
a-hemolysin (rHla). Lysates were prepared from the cells and analyzed by immunoblot using antibodies directed against IL-1b (left panel). Lysates
were analyzed by immunoblot with antibodies directed against actin (loading control, right/top panel). Processed IL-1b was detected in the cell
culture supernatants (right/bottom panel). A mature IL-1b (p18) standard is run in the far right lane.
doi:10.1371/journal.pone.0007446.g002
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of IL-18 (Fig. 3C). The activation of caspase-1 could be also be
detected in THP-1 cells treated with a-hemolysin using immuno-
blot analysis for the active p10 subunit of caspase-1 in the absence
of HKSA-priming. Intact NLRP3 and ASC expression was
required for a-hemolysin induced caspase-1 activation as well
(Fig. 3D). Immunoblot analysis also confirmed that the THP-1 cell
lines lacking NLRP3 or ASC do induce substantial pro-IL-1b
production in response to priming with HKSA (Fig. 3E). Together
these data suggest that the primary defect in a-hemolysin
responsiveness in NLRP3 inflammasome deficient cells is in
activation of caspase-1.
Mariathasan et. al. have demonstrated that bone marrow
derived macrophages secrete IL-1b in response to live S. aureus.
This IL-1b secretion in bone marrow derived macrophages was
not significantly reduced when the cells were treated with S. aureus
lacking a-hemolysin [32]. These reports suggest that either S.
aureus expresses multiple toxins that activate the NLRP3-
inflammasome or that a-hemolysin activates NLRP3 in some
but not all monocyte-derived cell lineages. We treated bone
marrow derived macrophages with HKSA, a-hemolysin, or the
combination of agents and measured IL-1b secretion. Surprisingly,
we found wild type, Nlrp3
2/2, and Asc
2/2 derived BMDM failed
to secrete significant levels of IL-1b to any of these stimuli (Fig. 4A).
This suggests that BMDM do not respond to a-hemolysin at the
doses used in these studies, unlike the other monocyte-derived cells
studied. These BMDM produced pro-IL-1b in response to LPS
but not to HKSA preconditioning at the doses used (Fig. 4B). As
observed by others, treatment of LPS-primed BMDM with ATP-
induced processing of pro-IL-1b and secretion of processed IL-1b
[30,31,32,33]. At the same time, a-hemolysin did not activate
processing of LPS-induced pro-IL-1b (Fig. 4B). Our data support
the fact that a-hemolysin can indeed activate the NLRP3
inflammasome, but suggests that this host response is likely to
vary depending on the site of infection and types of host
inflammatory cells present to combat it.
In addition to causing IL-1b secretion, a-hemolysin is known to
induce cell death in numerous cell types [22]. We found that a-
hemolysin induced death in THP-1 cells in a robust fashion, as
demonstrated by release of cytoplasmic LDH into the culture
media from THP-1 cells treated with the toxin (Fig. 5A & B.). This
activation of cell death was rapid, reaching maximal effect within
60 min. Paralleling our findings in studies of a-hemolysin-induced
IL-1b secretion, the mutant a-hemolysin failed to elicit cell death
at 1 hour (Fig. 5A), though at longer time points LDH release was
observed with the mutant. Also like IL-1b secretion, the induction
of cell death in THP-derived cells by a-hemolysin required intact
NLRP3 and ASC expression (Fig. 5B).
S. aureus a-hemolysin has been shown to induce both apoptosis
and necrotic cell death in peripheral blood mononuclear cells
[43,44]. Our lab and others have recently demonstrated that
NLRP3 activation leads to programmed necrosis, termed
Figure 3. S. aureus a-hemolysin induced IL-1b secretion requires the host NLRP3-inflammasome. (A) THP-1-derived cell lines stably
transduced with shRNA expressing retrovirus were treated with HKSA (10
6 particles/ml) or Hla (1.0 mg/ml) for 4 hours or 1 hour, respectively, or a
combination of the two, and IL-1b production determined by ELISA. The shRNA’s are directed to knock down expression as follows: shCON - negative
control (scrambled sequence with base content equal to shASC); shASC – shRNA directed against Apoptotic Speck Containing-protein; shNLRP3 –
shRNA directed against NLRP3. (B) Resting peritoneal macrophages were isolated from C57BL/6 mice which were either wild type (WT) or bearing
genetic deletion of the NLRP3 (Nlrp
2/2), ASC (Asc
2/2) or Caspase-1 (Casp1
2/2) gene, cultured and treated with HKSA and Hla as described in 2A.
Culture supernatant was removed and assayed for the presence of IL1b using ELISA. (C) THP-1-derived cell lines stably transduced with shRNA
expressing retrovirus, as described above, were treated with HKSA (10
6 particles/ml) or Hla (1.0 mg/ml) for 4 hours or 1 hour, respectively, or a
combination of the two, and IL-18 secretion determined by ELISA. Representative data from at least 3 independent experiments are shown. (D) THP-1
derived cell lines described in (A) were treated with S. aureus a-hemolysin for 1 hour. Cell lysates were analyzed for caspase-1 activation using
immunoprecipitation and immunoblot as described in the materials and methods. (E) THP-1-derived cell lines stably transduced with shRNA
expressing retrovirus described in (A) were treated with HKSA for 3 hours and cell lysates were analyzed for induction of pro-IL-1b expression using
immunoblot analysis (left panel). Equal loading was assessed using immunoblot analysis for actin (right panel). Representative data from at least 3
independent experiments are shown.
doi:10.1371/journal.pone.0007446.g003
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cell death and is distinct and independent of the process of
apoptosis, which normally results in an orderly disassembly of the
dying cells that limits inflammatory responses to the death. In
order to confirm that a-hemolysin causes NLRP3-dependent
pyronecrosis, we first sought to demonstrate that a-hemolysin-
induced death lacked hallmarks characteristic of apoptosis
including: activation of caspase-3, cleavage of PARP, and
intranucleosomal cleavage of DNA. Immunoblot analysis of
lysates from cells treated with a-hemolysin showed no evidence
of caspase-3 activation or cleavage of PARP, both of which could
be induced in the THP-1 cells by treatment with Staurosporine
(which is known to activate apoptosis) (Fig. 6A). Intranucleosomal
cleavage of DNA occurs in the setting of apoptosis and is reflected
by reduced propidium iodide staining (sub-G1 DNA content) of
fixed cells detected by flow cytometry. While staurosporine
induced accumulation of sub-G1 DNA content, a- hemolysin
treated cells maintained DNA content profiles similar to untreated
controls (Fig. 6B). Overall, these studies demonstrate that a-
hemolysin-induced NLRP3-mediated cell death lacks traditional
apoptotic features.
To demonstrate that a-hemolysin induces programmed necrosis
in THP-1 cells, we used Transmission Electron Microscopy to
examine the morphology of a-hemolysin treated cells. The a-
hemolysin treated cells lacked morphologic features of apoptotic
cells seen in staurosporine treated cells, including chromatin
condensation and blebbing of apoptotic bodies from the plasma
membrane (Fig. 6C). Instead they have necrotic morphology with
Figure 4. Murine Bone Marrow Derived macrophages are resistant to a hemolysin induced NLRP3-inflammasome activation. (A)
Bone marrow-derived macrophages were cultured from the femurs of C57BL/6 mice, which were either wild type (WT), Nlrp
2/2, Asc
2/2,o rCasp1
2/2.
The macrophages were subsequently pretreated with HKSA or without HKSA for 3 hours then treated for 1 hour with Hla (1 mg/ml) as described in
Fig. 2A. Culture supernatant was removed and assayed for the presence of IL-1b using ELISA. Representative data from 3 independent experiments
are shown. (B) Bone marrow-derived macrophages were cultured from the femurs of wild type C57BL/6 mice, as described in (A). The cells were then
pretreated with nothing (N), LPS (100 ng/ml, L), or HKSA (1610
6 particles, H) for 3 hours. The cells were then treated for 1 hour with nothing (N.T.),
1 mM ATP, commercial a-hemolysin (1 mg/ml, Hla), or recombinant a-hemolysin (1 mg/ml, rHla). Cellular lysates and culture supernatants were
prepared and subjected to immunoblot analysis with anti-IL-1b antibody.
doi:10.1371/journal.pone.0007446.g004
Figure 5. S. aureus induces NLRP3-inflammasome- dependent cell death in THP-1 cells. (A) THP-1 cells were treated with 1.0 mg/ml
recombinant wild type (W.T.) a-hemolysin or recombinant mutant (H35L) a-hemolysin for 4 hours. Treatment induced cell death was assayed at the
indicated time points by measuring LDH activity released into culture supernatant. Levels of LDH are reported as a percent of the maximal LDH
activity detected after detergent lysis. (B) THP-1 derived cell lines stably transduced with shRNA expressing retrovirus were treated with or without
Hla (1.0 mg/ml, Sigma Aldrich) for 1 hour and cell death was assayed by measuring LDH activity released into culture supernatant. Levels of LDH are
reported as a percent of the maximal LDH activity detected after detergent lysis. Representative data from at least 3 independent experiments are
shown.
doi:10.1371/journal.pone.0007446.g005
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well as intact nuclei with loose chromatin. Necrotic cell death
results in the release of the chromosomal protein HMGB1.
Release of HMGB1 is also observed from apoptotic cells in tissue
culture as a result of secondary necrosis, but this occurs at a much
later time point than is seen in primary necrosis [36]. Immunoblot
analysis of cell culture supernatants from a-hemolysin treated
THP-1 cells demonstrates that a-hemolysin induced death is
accompanied by early release of HMGB1 protein, which is not
seen in staurosporine treated cells (Fig. 6D). Staurosporine-
induced apoptotic death was confirmed in these cultures by
immunoblot analysis for PARP cleavage (Fig. 6D). Prior studies
have demonstrated that induction of IL-1b processing through
activation of the NLRP3-inflammasome in response to the pore-
forming toxin Nigericin requires intracellular potassium depletion.
Both NLRP3-inflammasome dependent IL-1b secretion and
necrotic cell death were inhibited when cells were treated with
S. aureus a-hemolysin in the presence of 130 mM KCl (Fig. 7A &
B). This data, combined with the inability of mutant a-hemolysin
to induce IL-1b secretion or rapid necrosis, suggests that S. aureus
a-hemolysin activates the inflammasome through potassium
depletion and not through direct interaction with other host
signaling proteins. In total, this work demonstrates that a-
hemolysin actually requires host NLRP3 signaling in order to
induce necrotic cell death.
Though the NLRP3 inflammasome activates the cysteine
proteinase, caspase-1, NLRP3- dependent programmed ne-
crosis has been shown to be independent of caspase activation.
Pretreatment of THP-1 cells with a cell permeable pancaspase
inhibitor did not block a-hemolysin induced cell death (Fig. 8A).
We confirmed the inhibitor was functioning by examining a-
hemolysin-mediated IL-1b secretion in the treated cells, which
was completely abrogated by treatment with caspase inhibitor
(Fig. 8B). We also studied induction of pyronecrosis in peritoneal
derived macrophages treated with a hemolysin. While a-
hemolysin induced release of HMGB1 into the culture
supernatant at levels equivalent to detergent induced lysis from
wild type peritoneal macrophages, Nlrp3
2/2 macrophages were
resistant to a-hemolysin induced HMGB1 release (Fig. 8C).
Consistent with our findings using caspase inhibitors, release of
Figure 6. S. aureus Hemolysin induces necrotic cell death in THP-1 cells. Lysates from THP-1 cells that were untreated (N.T.) or treated with
either Hla (1.0 mg/ml) or staurosporine (1 mM) for 4 hours were subjected to SDS-PAGE and immunoblot with antibodies directed to active caspase-3,
Poly ADP ribose polymerase (PARP), or actin. Representative data from 2 independent experiments are shown. (B) THP-1 cells were untreated (N.T.) or
treated with either Hla (1.0 mg/ml) or staurosporine (1 mM) over a 17 hour time course. At indicated times the cells were fixed and stained for DNA
content with propidium iodide and analyzed using flow cytometry. Cell counts are plotted against propidium iodide fluorescence, which indicates
DNA content of the cell. The bars on the histograms indicate the gate for subG1 DNA content (apoptotic cells). Histograms for cells treated for
4 hours are shown, the percent of cells containing subG1 DNA content at 4, 8, 17 hours are charted below the histograms. (C) THP-1 cells, untreated
(left) or treated with either Hla (1.0 mg/ml, middle) or staurosporine (1 mM, right), were processed and examined by transmission electron microscopy.
Normal cellular morphology is demonstrated in the untreated cells. Morphologic features of necrotic cell death including loss of plasma membrane
integrity and cytoplasmic contents as well as intact nuclei with loose chromatin are demonstrated in the Hla treated cells. Apoptotic morphology
with nuclear condensation and apoptotic body formation is demonstrated in a staurosporine-treated cell. (D) Culture supernatants from THP-1 cells
that were untreated or treated with either Hla (1.0 mg/ml) or staurosporine (1 mM)for 1 and 6 hours were subjected to SDS-PAGE and immunoblot
against HMGB1 (left panel). Cell pellets were analyzed for PARP cleavage using immunoblot (right panel). Representative data from at least 3
independent experiments are shown.
doi:10.1371/journal.pone.0007446.g006
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2/2 macrophages
(Fig. 8C). Combined, these data confirm that a-hemolysin
induced pyronecrosis is independent of caspase-1 activation and
IL-1b secretion, which is consistent with reports from other
groups.
Discussion
We have demonstrated that highly purified recombinant S.
aureus a-hemolysin is capable of inducing activation of caspase-1
through the NLRP3 inflammasome. Activation of NLRP3 by a-
hemolysin induces cytokine processing and programmed necrosis,
both of which can explain many of the pro-inflammatory
properties of a-hemolysin that have been observed in the past.
In fact, these studies identify the mechanism by which a-hemolysin
induces IL-1b secretion, an observation that was published almost
twenty years ago [22].
In the initial report of S. aureus activating NLRP3-mediated IL-
1b secretion, Mariathasan et. al. found that S. aureus lacking a-
hemolysin, b-hemolysin, or c- hemolysin still activated IL-1b
secretion [32]. Our findings using purified toxin clearly demon-
strate that NLRP3 is activated by a-hemolysin. Because bone
marrow derived macrophages do not respond robustly to a-
hemolysin in our studies, the findings of Mariathasan et al. are not
surprising. Additionally, given the large number of pore-forming
and membrane disrupting toxins produced by S. aureus, it seems
likely S. aureus may have redundant factors that activate NLRP3-
signaling. Supporting this possibility, we have found that other
pore-forming S. aureus toxins (particularly Panton Valentine
Leukocidin) also induce NLRP3-dependent cytolysis (data not
shown). Since some of these toxins exert differential cytolytic
activity based on cell type, the ability to activate NLRP3-mediated
signaling may be important in establishing infection in a variety of
infection sites [22].
The ability of a-hemolysin to activate programmed cell death in
host cells has been the subject of numerous studies. In early
studies, a-hemolysin was shown to activate apoptotic machinery in
studies carried out primarily in lympocyte derived cell lines [46].
This report demonstrated that apoptotic caspases were activated
and down stream apoptotic effects were observed, including
cleavage of a-fodrin and intranucleosomal DNA cleavage.
However, these effects were studied at times between 4 and
24 hours. A second report by this group later demonstrated that a-
hemolysin induced cell death, as measured by loss of membrane
integrity, occurred even if apoptotic machinery was inhibited [44].
Additionally, they demonstrated that a-hemolysin induced death
Figure 7. S. aureus a-hemolysin requires potassium efflux to
induce NLRP3 activation. THP-1 cells were cultured in media
containing 130 mM NaCl or 130 mM KCl for 30 min. then treated with
and without recombinant a-hemolysin (1 mg/ml) for 1 hour. (A) IL-1b
secretion into the culture supernatant was determined using ELISA. (B)
Cell death was determined by measuring LDH release and is expressed
as a percent of maximum LDH release (determined with detergent
lysis). The error bars represent Standard Deviation of triplicate
measurements. Asterisk (*) denotes cytokine levels below detectable
limits (4 pg/ml). Representative data from 2 independent experiments
are shown.
doi:10.1371/journal.pone.0007446.g007
Figure 8. S. aureus a-hemolysin induced necrotic cell death is independent of caspase-1. (A & B) THP-1 cells were pretreated with the pan-
caspase inhibitor Z-VAD(OMe)-FMK (+VAD) or DMSO vehicle (-VAD). The cells were then divided and either treated or not treated with a-hemolysin.
Cell culture supernatants were analyzed for cell death using LDH activity (A) and secreted IL-1b using ELISA (B). Asterisk (*) denotes cytokine levels
below detectable limits (4 pg/ml). Representative data from at least 3 independent experiments are shown. Cell death is reported as percent of
maximal lysis observed with detergent above LDH levels present in sterile culture media. (C) Resting peritoneal macrophages were isolated from
C57BL/6 mice, either wild type (WT) or bearing genetic deletion of the NLRP3 (Nlrp
2/2) or Caspase-1 (Casp1
2/2) gene, and left untreated (N.T.) or
treated with recombinant Hla (0.5 mg/ml) for 4 hours. Culture supernatant was removed and analyzed for the presence of HMGB1 using immunoblot
analysis (as described in Fig. 6). Detergent (Det.) lysis was carried out as an internal positive control for HMGB1 release in cells from each genotype for
each experiment. Representative immunoblots are presented from two independent experiments.
doi:10.1371/journal.pone.0007446.g008
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of HMGB1 into the culture supernatant. We now show that
pyronecrosis is activated very rapidly by a-hemolysin, in a
timeframe earlier than has previously been characterized for a
hemolyin-induced death and with features consistent with these
other reports. Namely, we report a-hemolysin induced death is
independent of caspase-activation, has morphologic features of
necrosis, and is accompanied by early release of HMGB1.
Interestingly, when taken out to 16 hours, we did observe some
cells with sub-G1 DNA content, which may represent activation of
apoptotic machinery in cells from the population that resisted
activation of pyronecrosis. Overall, we have demonstrated that, in
monocytic cells, activation NLRP3-dependent pyronecrosis by a-
hemolysin is the primary mechanism underlying the cytolytic
activity of the toxin.
The activation of host NLRP3 by a-hemolysin requires the
hemolytic activity of the toxin. Our data demonstrates that
mutations in the toxin that eliminate hemolytic activity also
eliminate the toxin’s cytolytic activity in monocyte derived cells
and ability to induce NLRP3-inflammasome signaling. A recent
study of a similar a-hemolysin mutant demonstrates that this
mutant toxin is capable of inducing an apoptotic host response
[47]. Our experiments also demonstrate that although mutant a-
hemolysin does not induce NLRP3-dependent IL-1b secretion, it
does induce cell death with a time delay (Fig. 5). We suspect that
this death may represent apoptotic death observed by others using
mutant a-hemolysin, though formal demonstration of this requires
further investigation. Interestingly, this mutation also renders the
toxin incapable of causing death in animal models of a-hemolysin
induced peritonitis, presumably due to reduced activation of
inflammatory signaling [48]. The a-hemolysin gene, Hla,i sa
critical virulence factor in cellulitis, mastitits, and pneumonia
models of S. aureus infection [49,50]. We speculate that activation
of inflammatory signaling through the inflammasome may be
essential for a -hemolysin to mediate virulence. In support of this
hypothesis, a-hemolysin deficient S. aureus fail to establish lethal
infection or induce significant pulmonary infection [7,11].
Additionally, immunization with mutant a-hemolysin protects
mice from S. aureus pneumonia and reduces IL-1b production in
the lungs of the challenged mice [12]. Furthermore, we have now
shown a monoclonal antibody, which is protective against S. aureus
pneumonia in passive immunization studies of mice, inhibits
NLRP3-mediated signaling in cultured cells (Fig. 1D) [13]. It is
certainly possible that host inflammatory responses and pro-
grammed necrosis could damage host tissue architecture and
compromise the innate capacity of these tissues to resist infection.
Further experimentation is clearly required to determine the role
of NLRP3 inflammasome signaling in the pathogenesis of S. aureus
infection. If this hypothesis is born out, inhibition of inflamma-
some signaling may turn out to be a useful adjuvant therapy to
appropriate antibiotic use in severe S. aureus infections.
Materials and Methods
Ethics Statement
All protocols used in this study were approved by the
Institutional Animal Care and Use Committees at the University
of North Carolina.
Preparation of recombinant a-hemolysin
E. coli (BL21/DE3) harboring a hexahistidine-tagged S. aureus a-
hemolysin (wild type and H35L mutant)-expressing plasmid,
construction described by Ragle and Bubeck Wardenburg [13],
were grown overnight in LB supplemented with kanamycin
(50 ug/ml). Overnight cultures were diluted 1:10 into 100 ml LB
with kanamycin (50 ug/ml) and grown for 3 hours. a-hemolysin
expression was induced by addition of IPTG to 1 mM. After
2 hours at 37u, the E. coli were harvested by centrifugation and
lysed in Dulbecco’s Phosphate Buffered Saline (D-PBS) supple-
mented with complete protease
TM inhibitor cocktail (Roche,
product # 04 693 116 001) by sonication. The lysate was clarified
by centrifugation at 13,000 x g for 30 min and applied to
immobilized nickel resin (PrepEase Histidine-tagged Protein
Purification Sample Kit, USB, product # 78810). The bound
protein was washed extensively (50 column volumes) with pyrogen
free tissue culture grade D-PBS (Invitrogen/Gibco, product #
14040-133) and eluted in D-PBS supplemented with 200 mM
imidazole. Imidazole was removed from the eluted proteins by size
exclusion chromatography: 2 sequential passages through a
sephadex G-25 (Disposable PD-10 Desalting Columns, G.E.
Healthcare, product # 17-0851-01) equilibrated with pyrogen
free PBS. Final protein preparations concentration was deter-
mined using Bradford protein assay reagent (Bio-Rad Protein
Assay, Bio-Rad, product # 500-0006) with albumin protein
standards, purity of the proteins was assessed using SDS-PAGE
analysis.
Mouse strain maintainance and care
The generation of Nlrp3
2/2, Asc
2/2, and Casp1
2/2 mice has
been described previously [30,51]. The mice were kindly provided
by Millenium Pharmaceuticals and Dr. Vishva Dixit at Genen-
tech, and Dr. Richard Flavell at Yale University, respectively. The
mice have been backcrossed onto the C57BL/6J genetic
background for at least nine generations. Age- and sex-matched
C57BL/6J mice purchased from The Jackson Laboratory (Bar
Harbor, ME) were used as wild-type controls. The mice were
maintained according to institutional policies.
Culture of mammalian cells
The construction of THP-1-derived cell lines expressing shRNA
targeting NLRP3 and ASC as well as control cell lines using
recombinant retrovirus has been previously described [36,42]. All
cell lines were maintained in RPMI Media 1640 (Invitrogen/
Gibco, product # 12633-012) supplemented with 10% fetal calf
serum and penicillin and streptomycin. Resting peritoneal
macrophages were obtained by peritoneal lavage of euthanized
mice with Hanks Buffered Saline supplemented with 10% fetal calf
serum and penicillin/streptomycin. Lavaged cells were counted
and plated at a density of 2610
6/ml in 96 well tissue culture
plates. Bone marrow-derived macrophages were prepared as
previously described [36]; briefly, bone marrow was harvested by
necroptic dissection of euthanized mice. The cells were resus-
pended in 25 mls/femur DMEM supplemented with 10% FBS
(Hyclone Characterized Fetal Bovine Serum, Thermo Scientific,
product # SH30071), L-glutamine (Invitrogen/GIBCO, product
# 21051-024), 100 mM Non-Essential Amino Acids (Invitrogen/
GIBCO, product # 11140-050), 20% L929 conditioned media,
and plated at 12.5 ml/100620 mm non-tissue culture treated
plates. The adherent bone marrow-derived macrophages were
cultured in DMEM with 20% L929 cell supernatant (as a source of
M-CSF) for 7 days. The cells were then treated as indicated
(treatments detailed below.)
Treatment of cultured cells with a-hemolysin
When indicated cells were preincubated with Heat Killed S.
aureus (HKSA, Invivogen, product # tlrl-hksa) at 1 particle/cell
(typically 10
6/ml) for 3 hours. S. aureus a-hemolysin (Sigma-
Aldrich, product # H9395) or recombinant a-hemolysin (prepa-
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culture supernatants and cell pellets were collected after
centrifugation at 13,000 xg for 10 min. LDH activity was
measured in supernatants using Cyto-tox ONE kit (Promega,
product # G7891) and a Fluorostar fluorescence plate reader
(BMG Technologies). IL-1b and IL-18 were measured in culture
supernatants using ELISA kits (R & D Systems, product # DLB50
and 7620) according to the manufacturer’s protocols. When
staurosporine treatment was used as a positive control for
apoptotic cell death, staurosporine solution (1 mM) was obtained
from Sigma-Aldrich (product # S6942) and added to the culture
to final concentration of 1 mM. When caspase inhibitors were
used, Z-VAD(OMe)-FMK, (Alexis Biochemicals, product # ALX-
260-039) was added to the cells to a final concentration of 20 mM
from a stock of inhibitor in DMSO at a concentration of 20 mM.
A similar volume of DMSO (1 mg/1 ml) was added to the control
cells. Cell pellets were fixed in 2% paraformaldehyde, 2.5%
gluteraldehyde, 0.15 M sodium phosphate, pH 7.4 solution for
studies involving electron microscopy.
Immunoblot analysis
Cell pellets were lysed using PBS supplemented with 1% Igepal,
protease inhibitor, 2 mM DTT and soluble lysates for immunoblot
analysis were generated by centrifugation at 13,000 xg for 15 min.
When indicated, culture supernatants are run on SDS PAGE for
analysis. Invitrogen precast gels (NuPAGE) were used for all gel-
based analyses. Proteins were transferred to nitrocellulose using the
Invitrogen iBlot system and immunoblot analysis carried out using
antibodies directed against: human and mouse IL-1b (R &D
Systems, product # AF-201-NA & AF-401-NA, respectively), anti –
active caspase-3 (Cell Signaling, product # 9662), anti-PARP (Cell
Signaling, product # 9542), anti-HMGB1 (Abcam, product #
ab18256), actin (Santa Cruz Biotechnology, product # sc-8432
HRP). HRP-conjugated anti-mouse and anti-rabbit secondary
antibodies were from Santa Cruz Biotechnology.
Activation of caspase-1 was assessed using an immunoprecip-
itation/immunoblot analysis previously described [52]. Cells were
cultured at 10
7 cells/ml and treated as indicated. Cellular lysates
for analysis of caspase-1 p10 were prepared by the addition of
proteinase inhibitors (complete
TM, Roche, product # 04 693 116
001) and NP-40 (final concentration 0.1%) to the treated cell
cultures followed by centrifugation at 13,000 xg for 10 min.
Caspase-1 and actin were then simultaneously immunoprecipitat-
ed by incubation with antibodies to caspase-1 p10 (Santa Cruz
Biotechnology, sc-515) and actin (Santa Cruz Biotechnology, sc-
7210) from Santa Cruz Biotechnology and Ultralink protein G
(Thermo Scientific/Pierce, product # 53125) overnight at 4uC.
The immunoprecipitated proteins were analyzed by immunoblot
with antibodies directed to caspase-1 (Imgenex, product # IMG-
5028) and actin (Santa Cruz Biotechnology, sc-8432 HRP).
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